H.R.4895 - Lowering Drug Costs for American Families Act - in support.
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.
Issues related to the Centers for Medicare and Medicaid Services - no specific legislation.
S.4017 - Ultra-Millionaire Tax Act of 2024 - in support.
H.R.7749 - Ultra-Millionaire Tax Act of 2024 - in support.
Duration: March 1, 2022
to
May 1, 2024
General Issues: Pharmacy , Medicare/Medicaid , Taxation/Internal Revenue Code , Government Issues , Budget/Appropriations , Health Issues
Spending: about $10,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2022: U.S. Senate, House of Representatives, White House Office, Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2024
PORT SIDE STRATEGIES, LLC terminated an engagement in which they represented New Venture Fund on May 16.
Original Filing: 301579490.xml
Lobbying Issues
H.R.4895 - Lowering Drug Costs for American Families Act - in support.
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Centers for Medicare and Medicaid Services - no specific legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4017 - Ultra-Millionaire Tax Act of 2024 - in support.
H.R.7749 - Ultra-Millionaire Tax Act of 2024 - in support.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2024
In Q1, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on April 17.
Original Filing: 301552690.xml
Lobbying Issues
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.
H.R.4895 - Lowering Drug Costs for American Families Act - in support.
H.R.485 - Protecting Health Care for All Patients Act of 2023 - opposed.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Centers for Medicare and Medicaid Services - no specific legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4017 - Ultra-Millionaire Tax Act of 2024 - in support.
H.R.7749 - Ultra-Millionaire Tax Act of 2024 - in support.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on Jan. 14.
Original Filing: 301524289.xml
Lobbying Issues
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.
S.142 - Preserve Access to Affordable Generics and Biosimilars Act - in support
S.150 - Affordable Prescriptions for Patients Act of 2023 - in support
S.148 - Stop STALLING Act - in support
S.1067 - Ensuring Timely Access to Generics Act of 2023 - in support
S.775 - Increasing Transparency in Generic Drug Applications Act - in support
S.79 - Interagency Patent Coordination and Improvement Act of 2023 - in support
H.R.4895 - Lowering Drug Costs for American Families Act - in support
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Centers for Medicare and Medicaid Services - no specific legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6498 - Billionaire Minimum Income Tax Act - in support.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on Oct. 17, 2023.
Original Filing: 301503333.xml
Lobbying Issues
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.
S.2305 - Biosimilar Red Tape Elimination Act - in support.
S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed.
H.R.4895 - Lowering Drug Costs for American Families Act - in support.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Centers for Medicare and Medicaid Services -- no specific legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to government shutdown.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on July 16, 2023.
Original Filing: 301477195.xml
Lobbying Issues
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.
H.R.485 - Protecting Health Care for All Patients Act of 2023 - opposed.
S. 1264 - SMART Prices Act - in support.
S. 1323 - End Price Gouging for Medications Act - in support.
S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed.
S. 1339 - Pharmacy Benefit Manager Reform Act - in support.
S. 1214 - RARE Act - in support.
S. 1114 - Expanding Access to Low-Cost Generics Act of 2023 - in support.
S.1067 - Ensuring Timely Access to Generics Act of 2023 - in support.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3936 - Tax Cuts for Working Families Act - opposed.
H.R. 3937 - Small Business Jobs Act - opposed.
H.R. 3938 - Build It in America Act - opposed.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Centers for Medicare and Medicaid Services -- no specific legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the debt ceiling.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on April 19, 2023.
Original Filing: 301457548.xml
Lobbying Issues
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax rates for the wealthy - no specific legislation.
Issues related to the Presidents Budget.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund , earning $10,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435145.xml
Lobbying Issues
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022
H.R.7529 - Plain Prescription Prices Act - in support
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.7502 - Babies over Billionaires Act of 2022 - in support
H.R.8558 - Billionaire Minimum Income Tax Act -- in support
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on Oct. 17, 2022.
Original Filing: 301406373.xml
Lobbying Issues
Lobbied in support of including drug pricing reforms in the reconciliation bill.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.8289 - Banning Misleading Drug Ads Act of 2022 - in support.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.7502 - Babies over Billionaires Act of 2022 - in support.
H.R.8558 - Billionaire Minimum Income Tax Act -- in support.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 5376 (P.L. 117-169) Inflation Reduction Act - in support.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on July 19, 2022.
Original Filing: 301388016.xml
Lobbying Issues
Lobbied in support of including drug pricing reforms in the reconciliation bill - in support.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.7473 Generic Substitution Noninterference Act - in support
H.R.7474 - Pharmaceutical Research Transparency Act of 2022 - in support
H.R.7529 - Plain Prescription Prices Act - in support
H.R.7828 - PRICED Act - in support
H.R.8289 - Banning Misleading Drug Ads Act of 2022 - in support
H.R.7472 - Discounted Drugs for Clinical Trials Act - in support
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.7502 - Babies over Billionaires Act of 2022 - in support.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, PORT SIDE STRATEGIES, LLC lobbied for New Venture Fund . The report was filed on April 18, 2022.
Original Filing: 301359774.xml
Lobbying Issues
Lobbied in support of including drug pricing reforms in the reconciliation bill.
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
1st Quarter, 2022
PORT SIDE STRATEGIES, LLC filed a lobbying registration on March 17, 2022 to represent New Venture Fund, effective March 1, 2022.
Original Filing: 301342769.xml
Issue(s) they said they’d lobby about: Issues related to drug pricing, transparency, and accountability. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...